Thyssenkrupp Nucera FY Profit After Tax Declines

thyssenkrupp nucera reported fiscal 2024/25 net income of about €5m (EPS €0.04) versus €11m a year earlier, with an improved full-year EBIT of €2m (vs. -€14m) despite slightly lower sales of €845m (from €862m); order intake collapsed to €348m from €636m and Q4 sales fell 28% to €182m with Q4 EBIT at -€1m. Management guided for fiscal 2025/26 order intake of €350–900m, sales of €500–600m and consolidated EBIT of -€30m to €0, signaling significant near-term earnings volatility and a recovery-dependent outlook despite the year-on-year EBIT improvement.

Analysis

thyssenkrupp nucera reported fiscal 2024/25 net income of about €5 million (EPS €0.04) versus €11 million a year earlier while full-year EBIT improved to €2 million from a negative €14 million; sales slipped to €845 million from €862 million. The positive swing in full-year EBIT suggests some operational recovery, but the small net profit and lower revenue indicate limited margin expansion and fragile demand.

Order intake collapsed to €348 million from €636 million and fourth-quarter sales fell 28% to €182 million with Q4 EBIT at -€1 million, unchanged year-over-year; these metrics point to weakening near-term demand and lower backlog visibility. The steep drop in orders increases execution risk for near-term revenue and heightens quarter-to-quarter volatility.

Management's fiscal 2025/26 guidance is wide: order intake €350–900 million, sales €500–600 million and consolidated EBIT between -€30 million and €0, signaling a recovery-dependent outlook and material earnings uncertainty. The breadth of the ranges and the moderately negative sentiment signal from market-data imply limited near-term upside absent clear, sustained order recovery.

Key Decisions for Investors

• Maintain a cautious stance on positions in thyssenkrupp nucera; consider holding or modestly reducing exposure until order intake and sales show sequential stabilization
• Monitor the next quarterly order intake and sales versus management guidance (order intake at or above the €350 million floor and sales moving into the €500–600 million range); treat movement toward the midpoint of guidance as a potential buy catalyst
• Given the wide EBIT guidance (-€30 million to €0), employ position-sizing discipline or consider hedging to limit downside risk ahead of the next earnings cycle
• Re-evaluate the investment case if management narrows guidance, reports consecutive quarters of improving order intake, or demonstrates consistent positive EBIT momentum